000 01487 a2200397 4500
005 20250517064154.0
264 0 _c20161213
008 201612s 0 0 eng d
022 _a1098-6596
024 7 _a10.1128/AAC.00426-15
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSchad, Caroline
245 0 0 _aDevelopment of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.
_h[electronic resource]
260 _bAntimicrobial agents and chemotherapy
_cFeb 2016
300 _a797-805 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAntiprotozoal Agents
_xchemistry
650 0 4 _aAziridines
_xchemistry
650 0 4 _aCathepsin B
_xantagonists & inhibitors
650 0 4 _aCysteine Proteinase Inhibitors
_xchemistry
650 0 4 _aLeishmania major
_xdrug effects
650 0 4 _aLeishmaniasis
_xdrug therapy
650 0 4 _aPapain
_xantagonists & inhibitors
650 0 4 _aTh2 Cells
_ximmunology
700 1 _aBaum, Ulrike
700 1 _aFrank, Benjamin
700 1 _aDietzel, Uwe
700 1 _aMattern, Felix
700 1 _aGomes, Carlos
700 1 _aPonte-Sucre, Alicia
700 1 _aMoll, Heidrun
700 1 _aSchurigt, Uta
700 1 _aSchirmeister, Tanja
773 0 _tAntimicrobial agents and chemotherapy
_gvol. 60
_gno. 2
_gp. 797-805
856 4 0 _uhttps://doi.org/10.1128/AAC.00426-15
_zAvailable from publisher's website
999 _c25475908
_d25475908